@article{article, title  = {{Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).}},

 url = {{}},

 year = {{2013}},

 month = {{6}},

 author = {{O'Brien ME and Gafaar RM and Popat S and Grossi F and Price A and Talbot DC and Cufer T and Ottensmeier C and Danson S and Pallis A and Hasan B et al}},

 doi = {{10.1016/j.ejca.2013.05.008}},

 journal = {{European Journal of Cancer}},

 note = {{Accessed on 2025/01/03}}}